FLCCC Alliance
Latest Updates

The Medincell SAIVE study: Ivermectin Reduces COVID-19 Infection 72%

Published On: January 5, 2023|
Print Friendly, PDF & Email

The Medincell SAIVE study, a randomized clinical trial, found that “ivermectin administered for 28 days demonstrated acceptable safety and tolerability without any unexpected safety signals.”

The objective of the study was to “provide prevention of Covid-19 infection for weeks or months with a single injection of a long-acting formulation of ivermectin based on MedinCell’s proprietary technology, BEPO.®”


Explore Similar Stories